FDA OKs New Lung Cancer Drug

Friday, 12 Jul 2013 12:37 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

 
The U.S. Food and Drug Administration approved a lung cancer drug made by Boehringer Ingelheim to treat patients who are suffering from late stage non-small cell lung cancer and whose tumors express a specific type of gene mutation.
 
The drug, Gilotrif, was approved along with a companion diagnostic kit that can help determine if a patient's lung cancer cells express the epidermal growth factor receptor (EGFR) gene mutation.
 
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and represents about 85 percent of all lung cancers. EGFR gene mutations are present in about 10 percent of NSCLC.
 
Lung cancer is the leading cause of cancer-related death among men and women, and according to the National Cancer Institute, an estimated 228,190 Americans will be diagnosed with, and 159,480 will die from, the disease this year.
 
The companion diagnostic kit, called therascreen EGFR RGQ PCR Kit, is made by Qiagen N.V.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Comments
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
 
Find Your Condition
You May Also Like
Around the Web
Most Commented

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

NEWSMAXHEALTH.COM
© Newsmax Media, Inc.
All Rights Reserved